Genoptix GXDX Stockholders File Securities Fraud Class Action Lawsuit Complaint Against Genoptix Over Alleged False & Misleading Statements.
A securities fraud class action lawsuit has been filed against Genoptix Inc. (“Genoptix”), a laboratory service provider that delivers diagnostic services to community-based hematologists and oncologists, and Genoptix’s directors and officers (collectively “Defendants”) in the United States District Court for the Southern District of New York on behalf of a class consisting of purchasers of Genoptix’s (symbol: GXDX) securities between July 31, 2009 and June 15, 2010, inclusive (the “Class Period”), alleging that Genoptix and its officers and directors violated federal securities fraud laws, including the Securities Exchange Act of 1934, by failing to disclose, among other things, that due to known trends and uncertainties, including increased competition and increased managed care pressures, Genoptix would be unable to grow and would have difficulty maintaining its current client base and that the reconfiguration of Genoptix’s sales force had severely impacted its ability to grow revenue, according to Genoptix securities fraud class action lawsuit news reports.
If You Have Thoughts On The Genoptix Securities Fraud Class Action Lawsuit, Share Your Class Action Comments Below.